Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Previous published data showed an impact of single-nucleotide polymorphisms in the VEGF A and VEGFR2 genes on the survival of patients with various malignancies, among others diffuse large B-cell lymphoma (DLBCL).
Patients And Methods: We investigated the role of four VEGF-A and two VEGFR-2 gene polymorphisms on the outcome of 273 patients with diffuse large B-cell lymphoma who were treated with R-CHOP within a prospective, randomized trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). The genomic DNA samples were analyzed using commercial DNA Probes (Applied Biosystems, USA) to detect single-nucleotide polymorphisms in the VEGF A rs699947, rs1570360, rs2010963, rs3025039 and rs1870377, and rs2305948 in the VEGFR2 receptor. Hundred healthy blood donors served as a control.
Results: There was no difference between the SNP allele frequencies in lymphoma patients compared to the control group for all investigated SNPs. None of the investigated SNPs was significantly associated with EFS or OS. After adjusting for the International Prognostic Index risk factors in a multivariate analysis, these results could be confirmed.
Conclusion: Single-nucleotide polymorphisms of the VEGF and VEGFR2 were not associated with a worse outcome in Caucasian patients with DLBCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.13526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma.
Ann Hematol
September 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunotherapy failure (ECF) is crucial. Methods.
View Article and Find Full Text PDFOvercoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus.
Cytotherapy
July 2025
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. Electronic address:
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of aggressive B-cell non-Hodgkin lymphoma, particularly in relapsed/refractory large B-cell lymphoma and mantle cell lymphoma. Despite its transformative potential, significant challenges persist in optimizing patient identification and referral pathways to ensure timely and equitable access. This expert consensus, developed through the Delphi methodology, analyzes key barriers to the referral process and proposes structured solutions to enhance collaboration between referring treatment centers (RTCs) and qualified treatment centers (QTCs).
View Article and Find Full Text PDFIsolated Thrombocytopenia as the Initial and Sole Manifestation of Bone Marrow B-Cell Lymphoma in an Elderly Female.
Eur J Case Rep Intern Med
September 2025
Respiratory Department, University Hospital Limerick, Limerick, Ireland.
Unlabelled: B-cell lymphomas are highly aggressive forms of lymphoma that commonly present with lymphadenopathy, systemic "B" symptoms, or organ involvement making them easy to recognize; however, a small percentage of B-cell lymphomas can present without any typical symptoms or evidence of lymphadenopathy, resulting in delayed recognition and management. Isolated thrombocytopenia without anaemia or leukopenia is an unusual presentation of B cell lymphomas and may be misdiagnosed as immune thrombocytopenia (ITP). Given the rarity of this presentation, we wish to report a case of a 76-year-old female who presented with palpitations, shortness of breath, and recurrent chest infections.
View Article and Find Full Text PDFThe effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
Blood Cell Ther
August 2025
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.
View Article and Find Full Text PDFDeep-learning based morphological segmentation of canine diffuse large B-cell lymphoma.
Front Vet Sci
August 2025
Pathobiology and Population Science, Royal Veterinary College, Hatfield, United Kingdom.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL) in humans, accounting for about 30-40% of NHL cases worldwide. Canine diffuse large B-cell lymphoma (cDLBCL) is the most common lymphoma subtype in dogs and demonstrates an aggressive biologic behaviour. For tissue biopsies, current confirmatory diagnostic approaches for enlarged lymph nodes rely on expert histopathological assessment, which is time-consuming and requires specialist expertise.
View Article and Find Full Text PDF